Search
Vaxcyte Inc
PCVXAdd to Watchlist
54.260USD
+0.230+0.43%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
7.11BMarket Cap
LossP/E TTM
More Details of Vaxcyte Inc Company
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Vaxcyte Inc Info
Ticker SymbolPCVX
Company nameVaxcyte Inc
IPO dateJun 12, 2020
CEOPickering (Grant E)
Number of employees414
Security typeOrdinary Share
Fiscal year-endJun 12
Address825 Industrial Road, Ste. 300
CitySAN CARLOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94070
Phone16508370111
Websitehttps://vaxcyte.com/
Ticker SymbolPCVX
IPO dateJun 12, 2020
CEOPickering (Grant E)
Company Executives of Vaxcyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
605.14K
-9.18%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
96.84K
+40.41%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
7.17K
-20.78%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
7.17K
-20.78%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
5.61K
-40.09%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
2.56K
-392.15%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
1.55K
-96.19%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Dr. Heath Lukatch, Ph.D.
Dr. Heath Lukatch, Ph.D.
Independent Director
Independent Director
--
--
Ms. Annie Drapeau
Ms. Annie Drapeau
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
605.14K
-9.18%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
96.84K
+40.41%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
7.17K
-20.78%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
7.17K
-20.78%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
5.61K
-40.09%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
2.56K
-392.15%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.27%
Fidelity Management & Research Company LLC
7.98%
T. Rowe Price Investment Management, Inc.
7.82%
RA Capital Management, LP
7.43%
BlackRock Institutional Trust Company, N.A.
6.02%
Other
61.48%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.27%
Fidelity Management & Research Company LLC
7.98%
T. Rowe Price Investment Management, Inc.
7.82%
RA Capital Management, LP
7.43%
BlackRock Institutional Trust Company, N.A.
6.02%
Other
61.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.10%
Investment Advisor/Hedge Fund
31.11%
Hedge Fund
17.88%
Venture Capital
9.47%
Research Firm
1.61%
Sovereign Wealth Fund
0.85%
Individual Investor
0.55%
Bank and Trust
0.46%
Pension Fund
0.45%
Institutional Shareholding
Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
718
151.93M
105.22%
-5.25M
2025Q4
699
144.28M
102.34%
-18.23M
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
13.39M
9.3%
+282.99K
+2.16%
Dec 31, 2025
Fidelity Management & Research Company LLC
11.52M
8%
+1.18M
+11.44%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
11.30M
7.85%
+2.98M
+35.85%
Dec 31, 2025
RA Capital Management, LP
10.72M
7.45%
-1.24M
-10.37%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
8.69M
6.04%
+295.02K
+3.52%
Dec 31, 2025
Wellington Management Company, LLP
5.97M
4.15%
+933.54K
+18.55%
Dec 31, 2025
State Street Investment Management (US)
4.98M
3.46%
+194.12K
+4.06%
Dec 31, 2025
Paradigm BioCapital Advisors LP
4.07M
2.83%
+283.26K
+7.48%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.39%
State Street SPDR S&P Biotech ETF
1.65%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.5%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
iShares Russell 2000 Value ETF
0.34%
View more
Harbor Health Care ETF
Proportion4.32%
ALPS Medical Breakthroughs ETF
Proportion2.39%
State Street SPDR S&P Biotech ETF
Proportion1.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
ProShares Ultra Nasdaq Biotechnology
Proportion0.58%
Invesco Nasdaq Biotechnology ETF
Proportion0.57%
iShares Biotechnology ETF
Proportion0.5%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.44%
iShares Russell 2000 Value ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
